BIOA B — BioArctic AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK26.74bn
- SEK24.84bn
- SEK2.00bn
Eisai and Biogen launch Alzheimer's drug Leqembi in China
Brief: BioArctic says Launched In China
Brief: Bioarctic Says FDA Accepts Filing Of Leqembi Sbla For IV Maintenance Dosing
Brief: BioArctic's Leqembi Approved In South Korea
Brief: Bioarctic AB Says No Dividend Is Paid For Financial Year 2023
Brief: BioArctic Q1 Operating Profit SEK -73.1 Million
Brief: BioArctic Says Eisai Projects Leqembi Revenue To Total JPY 56.5 Billion For FY 2024
Brief: BioArctic Gets Royalty Of SEK 18 Mln For Leqembi Q1 Sales
Brief: Bioarctic And Eisai Says Sign Research Evaluation Agreement Regarding BAN2802
Brief: BioArctic Partner Submits Leqembi sBLA To FDA
Brief: Bioarctic's Says As Per Eisai's Simulation Leqembi Sales Will Reach JPY 290 Bln For Financial Year 2026
Europe Research Roundup: Heineken NV, Integrafin Holdings Plc, Kingfisher
Brief: Bioarctic Proposes That No Dividend Is To Be Paid For 2023
Brief: BioArctic Says Sales Of Leqembi Totaled 1.1 Billion Yen In Q4 2023
Eisai expects 1,500 Alzheimer's patients in China launch, sees ‘huge’ growth
Eisai expects 1,500 Alzheimer's patients in China launch, sees ‘huge’ growth
Brief: BioArctic's Leqembi Approved For Treatment Of Alzheimer's Disease In China
Brief: BioArctic Says Leqembi To Be Launched In Japan For Alzheimer's Disease On December 20
GS starts BioArctic at 'buy' on strong Alzheimer's opportunity